|
Priyanka's Biotech Briefing
FDA’s July approvals delivered first drugs for three biotechs, while a proposed Medicare GLP-1 bridge and the GRAS pathway rollback raise access and authority questions.
The top 10 stories from Tue Aug 11, 2026 07:04 AM to Wed Aug 12, 2026 07:05 AM
Generated August 12, 2026 at 7:05 AM
|
|
|
#1 Does China Reimburse Its Most Innovative Drugs? Published 2026-08-12 China’s basic medical insurance covers some of the country’s most innovative drugs, with solid tumors as the leading indication and Chinese companies dominating the covered products. Covered by: insights.citeline.com |
#2 Axing Self-Affirmed GRAS Pathway Without Notification Spurs Resource, Authority Questions Published 2026-08-12 The decision to eliminate the self-affirmed GRAS pathway without requiring notification has prompted questions about regulatory authority and resource implications. Covered by: insights.citeline.com |
#3 New Drug Application for LAE002 (afuresertib) Accepted by China's National Medical Products Administration Published 2026-08-12 Laekna (2105.HK) said China’s NMPA CDE accepted its NDA for LAE002 (afuresertib) for treating patients, with details of the indication not provided in the available text. Covered by: prnewswire.com |
#4 Cost neutrality of BLC versus WLC in a real-world setting demonstrated by new OPTUM study in the U.S. Published 2026-08-11 Photocure ASA says a new U.S. OPTUM retrospective study found healthcare resource utilization and costs for blue light versus white light cystoscopy in non-muscle-invasive bladder cancer were cost-neutral. Covered by: prnewswire.com, prnewswire.com |
#5 With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development Published 2026-08-12 The article claims AI is increasingly used in drug development, including in pharma R&D and investment markets, to accelerate and reshape how new drugs are developed. Covered by: biospace.com |
#6 UCB Gets Scottish Funding For Zilbrysq, But England’s NICE Not Convinced Published 2026-08-11 UCB received Scottish funding for Zilbrysq, but England’s NICE has not been convinced it is cost-effective enough for NHS use. Covered by: insights.citeline.com |
#7 Silence causes uproar in rare blood cancer space as data sets high bar for competitors Published 2026-08-11 Silence Therapeutics reported mid-stage trial success for its siRNA drug in polycythemia vera, raising expectations for similar therapies from Takeda, Agios, and Disc Medicine. Covered by: biospace.com |
#8 Zydus’ Sentynl pens $475M deal for Mereo’s phase 3-ready rare genetic lung disease drug Published 2026-08-11 Sentynl Therapeutics agreed to a deal potentially worth $475 million for the option to market Mereo BioPharma’s phase 3-ready rare genetic respiratory disease drug in the U.S. Covered by: fiercebiotech.com |
#9 Opinion: Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugs Published 2026-08-11 A Medicare “Bridge” program intended to lower costs for GLP-1 weight loss drugs may add administrative complexity that could reduce practical patient access. Covered by: statnews.com |
#10 July FDA approvals deliver first products for three biotechs Published 2026-08-11 In July, the FDA approved six novel drugs, including the first oral PCSK9 inhibitor, delivering initial products for three biotech companies. Covered by: biocentury.com |
